We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 257093 for:    ALL
Previous Study | Return to List | Next Study

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

This study is not yet open for participant recruitment.
Verified October 2017 by Allergan
Sponsor:
ClinicalTrials.gov Identifier:
NCT03316898
First Posted: October 20, 2017
Last Update Posted: October 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Allergan
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: June 4, 2018
  Estimated Primary Completion Date: June 4, 2018 (Final data collection date for primary outcome measure)